EUVIMEDEUVIMED entdecken
Open Access

Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort

Domique Figarella-Branger iD, Carole Colin iD, Karima Mokhtari, Emmanuelle Uro-Coste, Ahmed Idbaih iD, Romain Appay, Emeline Tabouret iD, Mehdi Touat iD, Antoine Seyve iD, Catherine Carpentier, Caroline Dehais, François Ducray und 1 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Domique Figarella-Branger und 12 weiteren Autor:innen. Beteiligte Einrichtung: APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Oligodendroglioma, Chromosomes, Human, Pair 19, Chromosomes, Human, Pair 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Institut National du Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the POLA cohort, 3 pathological groups of CNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deleted have been described: group 1 (high mitotic count only), group 2 (microvascular proliferation MVP and no necrosis), and group 3 (MVP and necrosis).

Methods

494 patients from the POLA cohort, with a median follow-up of 96 months were included. To identify the impact of the pathological groups and contrast enhancement (CE) in group 1 on overall survival (OS) or progression-free survival (PFS), survival curves were obtained (Kaplan–Meier method) and compared (log-rank test). The prognostic value of clinical factors and CDKN2A homozygous deletion HD were also tested. Multivariate analysis was performed.

Results

Survival analysis demonstrated that the pathological groups were associated with both progression-free survival (PFS P = .01) and overall survival (OS P = .001). In group 1, patients with CE (1CE+) had a poorer prognosis compared to those without (OS P = .028, PFS P = .006). Further stratification into group 1CE−, group 1CE+, group 2, and group 3 provided clearer prognostic distinctions (OS P = .002, PFS P < .0001). Other prognostic factors included age (OS P < .0001, PFS P = .002), extent of surgical resection (OS P = .001, PFS P = .003), KPS (OS P < .0001, PFS P = 0.002), postoperative treatment (OS P = .007, PFS P < .0001), and CDKN2A HD (OS and PFS P < .0001). The pathological groups remained of prognostic significance for PFS in multivariate analysis.

Conclusions

Necrosis and CDKN2A HD are adverse prognostic factors of WHO grade 3 oligodendrogliomas, IDH-mutant, and 1p/19q co-deleted. Besides, in group 1 patients, lack of CE is a factor of better prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseOligodendrogliomaChromosomes, Human, Pair 19Chromosomes, Human, Pair 1MutationBrain NeoplasmsChromosome DeletionBiomarkers, TumorHumansFemaleMalePrognosisMiddle AgedAdultSurvival RateFollow-Up StudiesAgedNeoplasm GradingYoung AdultCyclin-Dependent Kinase Inhibitor p16Cohort StudiesAdolescent

Stichwörter der Autor:innen

CDKN2A HDCNS WHO grade 3 oligodendroglioma IDH-mutant and 1p/19q co-deletedcontrast enhancementmicrovascular proliferationmitosesnecrosis

Substanzen

Isocitrate DehydrogenaseCyclin-Dependent Kinase Inhibitor p16Biomarkers, TumorIDH1 protein, humanCDKN2A protein, human

Autor:innen und Institutionen

  • APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
  • Aix-Marseille Univ, CNRS, INP, Inst Neurophysiopathol, GlioME Team, Marseille, France.
  • Aix-Marseille Univ, Réseau PrEclinique et TRAnslationnel de Recherche en Neuro-Oncologie, Plateforme PETRA"TECH", Marseille, France.
  • Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute (ICM), Paris, France.
  • AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neuropathologie-Escourolle, Paris, France.
  • INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France.

ORCID-Profile: Domique Figarella-Branger, Carole Colin, Ahmed Idbaih, Emeline Tabouret, Mehdi Touat, Antoine Seyve

Förderung

  • Institut National du Cancer

Zitieren

APA

Figarella-Branger, D., Colin, C., Mokhtari, K., Uro-Coste, E., Idbaih, A., Appay, R., Tabouret, E., Touat, M., Seyve, A., Carpentier, C., Dehais, C., Ducray, F., & POLA network (2025). Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae221

Vancouver

Figarella-Branger D, Colin C, Mokhtari K, Uro-Coste E, Idbaih A, Appay R, et al. Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae221

BibTeX
@article{FigarellaBranger2025,
  author = {Figarella-Branger, Domique and Colin, Carole and Mokhtari, Karima and Uro-Coste, Emmanuelle and Idbaih, Ahmed and Appay, Romain and Tabouret, Emeline and Touat, Mehdi and Seyve, Antoine and Carpentier, Catherine and Dehais, Caroline and Ducray, François and POLA network, POLA network},
  title = {Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: Lessons from the French POLA cohort},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae221}
}
Kostenlos starten →